Insights
Regulatory intelligence analysis & commentary
Deep-dive analysis, trend reports, and expert commentary on the regulatory, clinical, and funding landscape across biologics, regenerative medicine, and life sciences.
Featured
FDA Regenerative Medicine Enforcement: What Changed in 2025 and What to Expect
An analysis of FDA enforcement trends targeting unapproved stem cell and exosome products, including new compliance requirements under the updated HCT/P framework.
The Exosome Therapy Regulatory Landscape: Current Status and Pathway Analysis
A comprehensive overview of exosome-based therapeutics regulation, including the FDA's evolving position, clinical trial requirements, and the distinction between 351(a) and 351(k) pathways.
FDA Regenerative Medicine Enforcement: What Changed in 2025 and What to Expect
An analysis of FDA enforcement trends targeting unapproved stem cell and exosome products, including new compliance requirements under the updated HCT/P framework.
The Exosome Therapy Regulatory Landscape: Current Status and Pathway Analysis
A comprehensive overview of exosome-based therapeutics regulation, including the FDA's evolving position, clinical trial requirements, and the distinction between 351(a) and 351(k) pathways.
Biotech Funding Q1 2026: Where Capital Is Flowing in Regenerative Medicine
Analysis of venture capital, Series A-C, and IPO activity in the regenerative medicine sector, with momentum indicators for cell therapy, gene therapy, and exosome platforms.
FTC Health Claims Enforcement: Pattern Analysis and Red Flag Detection
Reviewing recent FTC enforcement actions against health product marketers, identifying common violation patterns, and mapping the compliance boundaries for structure/function claims.
Clinical Trial Momentum in Cell Therapy: 2026 Landscape Report
Tracking the acceleration of cell therapy clinical trials across phases, therapeutic areas, and geographies — with momentum scoring for key technology platforms.
How the Technology Momentum Index Works: Methodology Deep Dive
A detailed explanation of BioIntel.io's proprietary TMI scoring system — how we weight research velocity, trial activity, funding, regulatory signals, and commercial traction.
Gene Therapy Regulatory Update: FDA Guidance and Approval Trends
Analyzing the latest FDA guidance on gene therapy products, accelerated approval pathways, and the growing pipeline of BLA submissions in the AAV and lentiviral vector space.
AI in Regulatory Compliance: How Machine Learning Is Transforming Biotech Intelligence
Exploring how AI-powered tools are changing regulatory affairs — from automated signal detection to predictive enforcement modeling and claim compliance screening.
Weekly Intelligence Digest
Get the week's most important regulatory signals, technology momentum shifts, and enforcement actions delivered to your inbox every Monday.
Subscribe Free